Creative Medical Technology Files S-1 for Highly Dilutive Public Offering to Fund Clinical Trials
CELZ sits 32% above its 52-week low of $1.504 on light trading volume (0.1× avg).
Summary
Creative Medical Technology Holdings filed an S-1 registration statement for a public offering of common stock and warrants, aiming to raise an estimated $5.34 million to fund clinical trials and operations, but signaling significant potential dilution.
Key Events · Financing and Capital Events · CELZ
-
Proposed Public Offering
Creative Medical Technology Holdings filed an S-1 to register a public offering of up to 3,045,685 shares of common stock, 6,091,371 public warrants, and 3,045,685 pre-funded warrants.
-
Estimated Capital Raise
The company aims to raise approximately $5.34 million in net proceeds from the offering, based on an assumed price of $1.97 per unit. This is a substantial amount relative to its current market capitalization.
-
High Potential Dilution
If all common stock and warrants registered in this offering are eventually issued and exercised, it could increase the outstanding share count by over 300% (12,182,741 new shares vs. 3,696,668 current shares), posing a significant dilutive risk.
-
Funding for Clinical Programs
The proceeds are intended to fund critical clinical trials for chronic lower back pain (AlloStemSpine®) and Type I Diabetes (CELZ-201 CREATE-1), continue the IPScelz™ program, and provide working capital, extending the cash runway through December 2027.
Analysis · CELZ · Life Sciences
This S-1 filing signals Creative Medical Technology Holdings' intent to raise approximately $5.34 million through a public offering of common stock, public warrants, and pre-funded warrants. While the capital is crucial for funding ongoing clinical trials for chronic lower back pain and Type I Diabetes, and extending the cash runway through December 2027, the offering carries substantial potential dilution. If all shares and warrants registered in this offering are eventually issued and exercised, it could increase the outstanding share count by over 300%. This follows a pattern of dilutive financing for the zero-revenue biotech.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELZ was trading at $1.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $1.50 to $6.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.